Kwality Pharmaceuticals Ltd. FY26 cash flow falls to Rs 16.59 crore

Kwality Pharmaceuticals recorded FY26 cash flow from operating activities of Rs 16.59 crore, down from Rs 52.72 crore in FY25, while profit after tax rose to Rs 67 crore and trade receivables reached Rs 280 crore, according to its historical financial statements.

Why did Kwality Pharmaceuticals' FY26 operating cash flow fall?

Kwality Pharmaceuticals' cash flow from operating activities fell by Rs 36.13 crore in FY26, even as revenue and reported profit increased. Operating cash flow was Rs 16.59 crore in FY26, compared with Rs 52.72 crore in FY25, while profit after tax rose by Rs 27 crore to Rs 67 crore. The presentation does not provide a detailed operating-cash-flow reconciliation explaining the movement.

The operating-cash-flow result also reversed the prior trend in the historical statement. Cash generated from operations had increased from Rs 41.38 crore in FY23 to Rs 42.98 crore in FY24 and Rs 52.72 crore in FY25, before declining in FY26. In contrast, FY26 earnings before interest, tax, depreciation and amortisation, or EBITDA, rose to Rs 118 crore from Rs 80 crore in FY25.

How much did Kwality Pharmaceuticals' receivables increase in FY26?

Kwality Pharmaceuticals' trade receivables rose to Rs 280 crore in FY26 from Rs 154 crore in FY25, an increase of Rs 126 crore. That increase was the largest movement among the listed current assets and exceeded the Rs 122 crore overall increase in current assets, which reached Rs 406 crore from Rs 284 crore.

Revenue from operations increased by Rs 133 crore to Rs 503 crore in FY26, compared with Rs 370 crore in FY25. Receivables therefore rose almost alongside the full annual revenue increase, whereas inventories declined by Rs 5 crore to Rs 78 crore. The supplied balance sheet does not disclose the ageing, customer concentration, collection terms or subsequent collection of the Rs 280 crore receivables balance.

The build-up had already been underway before FY26. Trade receivables rose from Rs 72 crore in FY23 to Rs 115 crore in FY24 and Rs 154 crore in FY25, then increased by a further Rs 126 crore in FY26. This balance-sheet pattern is consistent with a larger amount of reported sales remaining unpaid at year-end, but the presentation alone does not assign a specific reason for the increase.

Did Kwality Pharmaceuticals' reported earnings continue to rise in FY26?

Kwality Pharmaceuticals' reported earnings continued to rise in FY26, with profit after tax increasing to Rs 67 crore from Rs 40 crore in FY25. Revenue from operations grew 36% on the presentation's rounded figures, from Rs 370 crore to Rs 503 crore, while gross profit increased from Rs 188 crore to Rs 245 crore.

EBITDA increased by Rs 38 crore to Rs 118 crore in FY26. Employee benefits expense rose to Rs 54 crore from Rs 44 crore, other expenses rose to Rs 72 crore from Rs 64 crore, and cost of goods sold increased to Rs 258 crore from Rs 182 crore. Finance cost remained Rs 10 crore in both FY25 and FY26, while depreciation and amortisation increased by Rs 1 crore to Rs 19 crore.

Profit before tax reached Rs 89 crore in FY26 versus Rs 54 crore in FY25, and tax expense increased to Rs 24 crore from Rs 14 crore. The profit-and-loss statement therefore shows higher accounting profit through the income statement, while the cash-flow statement reports lower operating cash generation. These are separate reported measures and the presentation does not reconcile their FY26 difference line by line.

How did investment and financing flows affect Kwality Pharmaceuticals' cash balance?

Kwality Pharmaceuticals spent Rs 34.90 crore on investing activities in FY26 and generated Rs 7.03 crore from financing activities, yet cash and cash equivalents ended the year at Rs 73 lakh. Investing cash outflow increased from Rs 28.52 crore in FY25, while financing cash flow changed from an outflow of Rs 14.44 crore in FY25 to an inflow in FY26.

The balance sheet shows property, plant and equipment of Rs 150 crore in FY26, up from Rs 144 crore in FY25, and capital work in progress of Rs 17 crore after a nil balance in FY25. Intangible assets increased to Rs 6 crore from Rs 2 crore. These asset movements appear alongside the Rs 34.90 crore investing outflow, although the presentation does not allocate that outflow by project or asset category.

Borrowings also increased in FY26. Non-current borrowings rose to Rs 29 crore from Rs 15 crore, and current borrowings rose to Rs 101 crore from Rs 97 crore. Trade payables increased to Rs 102 crore from Rs 56 crore, while cash and bank balances reported separately were Rs 1 crore at FY26 year-end, down from Rs 12 crore in FY25.

What is Kwality Pharmaceuticals planning after FY26?

Kwality Pharmaceuticals' management targets FY27 revenue of more than Rs 720 crore, EBITDA of about Rs 189 crore to Rs 196 crore, an EBITDA margin of 27% to 28%, and profit after tax of Rs 122 crore. The FY27 plan follows FY26 revenue of Rs 503 crore, EBITDA of Rs 118 crore and profit after tax of Rs 67 crore.

Management's stated operating actions include commercialising its first biologic, Erythropoietin, in the first half of the next financial year, expanding oncology, biologics and hormone capacity, and advancing formulations through bio-equivalence studies. The presentation says four of five manufacturing plants are approved under European Union Good Manufacturing Practice, or EU-GMP, standards, and it lists more than 40 bio-equivalence programmes covering more than 40 molecules for regulated markets.

For FY29, management presents a revenue milestone of more than Rs 1,000 crore and a target EBITDA margin of more than 30%, compared with more than 24% shown for FY26 in its margin waterfall. It also identifies about Rs 260 crore of capital expenditure, product mix, operating leverage, higher fillings, export-led margin stability, research and development, and complex products as elements of that margin-expansion plan.

Conclusion

Kwality Pharmaceuticals' FY26 statements show a separation between accounting profit and operating cash generation. Revenue increased to Rs 503 crore and profit after tax to Rs 67 crore, but operating cash flow fell to Rs 16.59 crore as trade receivables reached Rs 280 crore and investing outflow rose to Rs 34.90 crore. Year-end cash and cash equivalents were Rs 73 lakh.

The next disclosures to watch are whether receivables are collected, whether operating cash flow recovers, and how the company funds its stated expansion. Management's FY27 plan calls for revenue above Rs 720 crore and profit after tax of Rs 122 crore, while Erythropoietin commercialisation is scheduled for the first half of the next financial year.